Clinical Trial Update: (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update for BLU-285 in gastrointestinal stromal tumors and other relapsed/refractory solid tumors; results posted after completion of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors
• Other Relapsed or Refractory Solid Tumors

Drugs mentioned

• BLU-285

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2021-06-22